Will Adjuvant Pembrolizumab Be an Effective Therapy for High-Risk Melanoma?
Source: Cancer Network, June 2019
CHICAGO—Investigators are now enrolling patients for a phase III trial, KEYNOTE-716, to assess the efficacy and safety of adjuvant pembrolizumab in adult and pediatric patients with surgically resected high-risk stage II melanoma. The study design was presented (abstract TPS9596) during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31–June 4 in Chicago.
In the KEYNOTE-054 trial, the immunotherapy pembrolizumab as adjuvant therapy has yielded significantly longer recurrence-free survival compared with placebo in patients with stage III melanoma (75.4% vs 61.0%, respectively). Based upon these promising results, the investigators initiated KEYNOTE-716, a two-part (adjuvant and rechallenge/crossover), randomized, double-blind, placebo-controlled, phase III study. Patients are currently being enrolled in Australia, Belgium, Brazil, Canada, Chile, France, Israel, Poland, Spain, Switzerland, the United Kingdom, and the United States.